Verseau Therapeutics
company
About
Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
Verseau Therapeutics has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Oct 21, 2019 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 21, 2019 | Series Unknown | $50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Verseau Therapeutics is funded by 2 investors.
InHarv Partners
and 3sbio
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
3sbio
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
